Real-World Evidence: Multicenter Efficacy and Toxicity Analysis of Nintedanib With Docetaxel as Second-Line Treatment in Mexican Patients With Advanced Lung Adenocarcinoma
- DOI
- 10.1200/jgo.19.00330
- Published
- 2020-11
- Container
- JCO Global Oncology
- Publisher
- American Society of Clinical Oncology (ASCO)
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1200/jgo.19.00330,
title = {Real-World Evidence: Multicenter Efficacy and Toxicity Analysis of Nintedanib With Docetaxel as Second-Line Treatment in Mexican Patients With Advanced Lung Adenocarcinoma},
author = {Jeronimo Rafael Rodríguez-Cid and Saul Campos-Gomez and Vanessa García-Montes and Manuel Magallanes-Maciel and Rodrigo Rafael Flores-Mariñelarena and Valeria Michelle Fernández-Garibay and Iván Romarico González-Espinoza and Juan Paulo Ceja-García and Juan Carlos Cázarez-Price and Luis Martínez-Barrera and Leopoldo Barriguete-Parra and Carlos Jose Zuloaga-Fernandez and Roberto Kuri-Exsome and David Suárez-García and Jorge Ignacio Gonzalez-Villanueva and Noé Flores-Anaya and Jose Antonio Acevedo-Delgado and Alma Magdalena Astorga-Ramos and Raquel Gerson-Cwilich and Alberto Villalobos-Prieto and Claudia Rodríguez-Silva and Maria Fernanda Noriega-Iriondo and Leticia Vázquez-Cortés and Eusebio Perales-Rodríguez and Alicia Acosta-Espinoza and Yareni Perez-Lozano and Daniel Capdeville-García and Jorge Arturo Alatorre-Alexander},
year = {2020},
journal = {JCO Global Oncology},
doi = {10.1200/jgo.19.00330},
url = {https://doi.org/10.1200/jgo.19.00330}
}RIS
TY - JOUR TI - Real-World Evidence: Multicenter Efficacy and Toxicity Analysis of Nintedanib With Docetaxel as Second-Line Treatment in Mexican Patients With Advanced Lung Adenocarcinoma AU - Jeronimo Rafael Rodríguez-Cid AU - Saul Campos-Gomez AU - Vanessa García-Montes AU - Manuel Magallanes-Maciel AU - Rodrigo Rafael Flores-Mariñelarena AU - Valeria Michelle Fernández-Garibay AU - Iván Romarico González-Espinoza AU - Juan Paulo Ceja-García AU - Juan Carlos Cázarez-Price AU - Luis Martínez-Barrera AU - Leopoldo Barriguete-Parra AU - Carlos Jose Zuloaga-Fernandez AU - Roberto Kuri-Exsome AU - David Suárez-García AU - Jorge Ignacio Gonzalez-Villanueva AU - Noé Flores-Anaya AU - Jose Antonio Acevedo-Delgado AU - Alma Magdalena Astorga-Ramos AU - Raquel Gerson-Cwilich AU - Alberto Villalobos-Prieto AU - Claudia Rodríguez-Silva AU - Maria Fernanda Noriega-Iriondo AU - Leticia Vázquez-Cortés AU - Eusebio Perales-Rodríguez AU - Alicia Acosta-Espinoza AU - Yareni Perez-Lozano AU - Daniel Capdeville-García AU - Jorge Arturo Alatorre-Alexander PY - 2020 JO - JCO Global Oncology DO - 10.1200/jgo.19.00330 UR - https://doi.org/10.1200/jgo.19.00330 ER -
APA
Rodríguez-Cid, J. R., Campos-Gomez, S., García-Montes, V., Magallanes-Maciel, M., Flores-Mariñelarena, R. R., Fernández-Garibay, V. M., González-Espinoza, I. R., Ceja-García, J. P., Cázarez-Price, J. C., Martínez-Barrera, L., Barriguete-Parra, L., Zuloaga-Fernandez, C. J., Kuri-Exsome, R., Suárez-García, D., Gonzalez-Villanueva, J. I., Flores-Anaya, N., Acevedo-Delgado, J. A., Astorga-Ramos, A. M., Gerson-Cwilich, R., Villalobos-Prieto, A., Rodríguez-Silva, C., Noriega-Iriondo, M. F., Vázquez-Cortés, L., Perales-Rodríguez, E., Acosta-Espinoza, A., Perez-Lozano, Y., Capdeville-García, D., & Alatorre-Alexander, J. A. (2020). Real-World Evidence: Multicenter Efficacy and Toxicity Analysis of Nintedanib With Docetaxel as Second-Line Treatment in Mexican Patients With Advanced Lung Adenocarcinoma. JCO Global Oncology. https://doi.org/10.1200/jgo.19.00330
Source records
- crossref · retrieved 2026-09-25T20:22:17.362Z